Company Address:
Manhattan Scientifics
The Chrysler Bldg.
32nd Floor
405 Lexington Ave.
New York, N.Y.
10174
USA
 Phone:
(212) 551-0577
 Website:
www.mhtx.com
 Ticker:
MHTX
 Exchange:
OTC BB
FREE E-MAIL ALERTS

  • ABOUT HAWK
  • HAWK CLIENTS
  • HAWK SERVICES
  • CONTACT HAWK
  • ch
The Chrysler Bldg. • 32nd Floor • 405 Lexington Ave. • New York • N.Y. • 10174 • USA • www.mhtx.com
Investor Contact: Frank N. Hawkins, Jr. or Julie Marshall · Hawk Associates Inc. · (305) 451-1888 · www.hawkassociates.com
MHTX Acquires Senior Scientific To Speed Applications of Early Cancer Detection and Treatment Technology. MHTX Revenue Triples in 2010 vs. 2009.
ALERT: Wall Street Journal Covers Breast Cancer Detection Technology in March 1 article entitiled "Researchers Create Better Ways To Spot Cancer Cells"


Since its inception Manhattan Scientifics Inc. has been a technology developer that nurtures financially promising technologies with potential global commercial applications. The company and its affiliates now own a significant IP portfolio and patents in high-strength metals, early cancer detection, alternative energy, hydrogen fuel cells and computer 3D touch haptics.

The company’s business model is to commercialize, bringing products to market to create profit for its shareholders through partnerships with manufacturers and licensees of its patents.

Manhattan Scientifics has enjoyed a “special informal relationship" and a successful history in tech-transfer from the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL).

An example of this relationship was the seed funding and launch of Novint Technologies, which acquired the exclusive, perpetual, global license to the Haptics touch technology from Sandia National Labs and now trades as a listed company in the Over-the-Counter Bulletin Board under ticker symbol NVNT. For more information, visit http://www.novint.com.


Differentiators

Nanomedicine

Manhattan Scientifics is collaborating with Dr. Edward Flynn, owner of Senior Scientific, to commercialize a nano-medicine technology -- specifically a biomagnetic detection of cancer and other diseases through magnetic field sensors that make it possible to identify and image small clusters of cancer cells increasing the possibility of finding cancer at a much earlier stage than is currently possible

NanoTitanium

Manhattan Scientifics owns exclusive rights to the key patents and IP portfolio to produce and market NanoTitanium and other ultra fine grain nano-structured metals. The company acquired Metallicum together with its patent rights for new ultra fine grain metals that may advance the medical device industry, particularly for dental implants, cardiovascular stents and for a wide range of prosthetic applications including artificial knees, shoulders, and hips. NanoTitanium is highly compatible with bone and is thought to provide stronger, faster bonding with improved strength, biocompatibility, longer life and improved wear and tear. To date more than $12 million has been directed toward developing the process. Dr. Lowe has been dubbed one of LANL’S “technology commercialization all-stars.”

Alternative Energy Technologies

Manhattan Scientifics is pursuing several potential solutions to the global alternative energy need as it relates to personal, 2-wheel transportation, particularly in Asia. The company won Time Magazine’s “Invention of the Year” award for its fuel cell Aprilia concept bicycle/fuel cell engine in 2001. MHTX owns the patents and IP technology for the award winning NovArs hydrogen powered fuel cell engine. Light weight and portable, it may be ideal to provide an inexpensive and environmentally friendly "green" system to drive scooters, bicycles, power tools, portable electronics, wheel chairs, golf carts and home emergency power.

MicroFuel Cell

Manhattan Scientifics provided seed funding for former Los Alamos National Laboratory scientist Robert Hockaday, who is developing a flat printed fuel cell designed to provide an “always on” energy source to power micro-electronics such as cellular telephones and pagers. Manhattan Scientifics owns the worldwide right to the patented technology. To date, the micro fuel cell has not been commercialized.

Haptics

Manhattan Scientifics provided $4.5 million seed funding to launch Novint Technologies Inc. The patented Novint Falcon, a computer game controller, enables the ability to touch and realistically feel images on a computer screen including texture, weight, motion and viscosity. The company is gaining recognition and growing rapidly, recently signing an agreement with EA games, whereby the company will create games compatible with the controller.

TECHNOLOGY AND BACKGROUND

Manhattan Scientifics began as a technology incubator. Early in its history it worked on acquiring several technologies in the fields of holographic data storage, water purification, alternative energy, advanced computer haptics and most recently, nanotechnology. The majority of MHTX’s commercial technologies come from U.S. government laboratories in New Mexico. During 2000, Manhattan Scientifics had a market capitalization approaching $900 million, about 60 times the company's present market cap, despite the fact that the company’s intrinsic value is worth many times more today than it was in year 2000.

Scientific Advisory Board

Dr. Terry Lowe – previously served as deputy director of the Materials Science and Technology division.

Dr. Arthur Kaufman,Previously Co-founder and Chief Scientist of H-Power.

Dr. Arthur Koschany – Mid-Range Fuel Cell Scientist, Passau, Germany.

Dr. Martin Cooper – 28 years chief technical officer with Motorola. “Father” of the cellular telephone.

Donald J. Sandstrom – 42 years with LANL. Materials Science Technology Division Leader.

Dr. Henry Rack – received his B.S., M.S. and Sc.D in Metallurgy from MIT. Recent News
Fortune: Manhattan Scientifics is a Leader in the Race for a Better Mammogram
Manhattan Scientifics CEO Issues Letter to Shareholders
Alzheimer’s Disease Patent Issued To New Mexico Physicist Edward R. Flynn, Ph.D
“Breast Cancer Research” Publishes Key Study; Cancer-Sensing Technology is Radiation-Free and 100 X More Sensitive Than Mammograms
Watching Cancer Cells Disappear During Therapy

    Risk Factors
  • Access to sufficient capital to bring product to market; to defend its patents; to surpass its competitors
  • No significant revenue or earnings
  • Ability to recruit additional senior management
  • Potential technical obsolescence
  • Numerous well-capitalized competitors

The Outlook MHTX continues its role as pioneer in the fields of nano technology, alternative energy and advanced computing.

Carpenter Technology Corp. (CRS) will develop and market a new new class of high-strength metals under exclusive license to MHTX and Los Alamos National Labs. The contract includes minimum annual payments over a four year period with royalty payments as a percent of gross sales. The ultra fine grain metals have broad applications in medicine and industry. The agreement is providing positive cash flow and profitability to MHTX.

MHTX has acquired full commercial rights to the body of work of nuclear physicist Edward R. Flynn, Ph.D. and his company Senior Scientific LLC. His breakthrough technology focuses on the emerging field of nanomedicine, with emphasis on the early detection and localization of cancer and other diseases, providing image-guided therapy for treatment.

Early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors while they are only 1% that large, resulting in an hundred-fold increase in sensititivy and early detection.

When fully developed and commercialized, Dr. Flynn's biomagnetic -based system will be 100% radiation free, unlike current radiation-based mammogram tests. His approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. The method yields high contrast images of tumors compared to normal cells. This makes it possible to identify and image tiny clusters of cancer cells providing the ability to find cancer at substantially earlier stages than is presently possible.

To reduce harm from over-treatment and radiation, new medical guidelines recently issued by the U.S. Preventative Services Task Force recommended that women begin regular breast cancer screening at age 50, rather than at age 40. "Annual mammograms for most women in their 40's have more drawbacks than benefits. "a report said.

The company also has a joint project with Carpenter and Cochlear to create customized metals that integrate with human tissue to produce longer lasting prosthetics

With the announcement of FY 2010 financial results that tripled its revenue in year 2010 and reduced its loss to $43,000 from a loss of $446,000 in year 2009, MHTX also announced a major financial milestone with the removal by its auditors of the “going concern” qualification in its audit opinion. Management said, “We are sufficiently capitalized to manage and run our current business operations without the need for additional capital and we continue exploring with pharmaceutical companies and device manufacturers for potential industrial partners for our “cancer project”. Our focus is to commercialize nanotechnologies for metals and medical treatment sourced from laboratories in New Mexico.”

Management
CEO, President and Chairman-
Emmanuel Tsoupanarias

Non-Executive Chairman of Manhattan Scientifics, a member of the Board of Directors of Novint Technologies, Inc.-
Marvin Maslow

Director-
Leonard Friedman

Director-
Frank Georgiou

Director-
Chris Theoharis

Special Legal Counsel-
Larry Schatz, Esq.

Back To Top